Sensorion Announces Results from 2017 Annual General Meeting: Appointments of Dominique Costantini and Nawal Ouzren to Company’s Board of Directors Approved

Read

Sensorion takes a key step towards phase 2 with SENS-401 thanks to the positive results obtained in the phase 1 clinical trial

Read

Sensorion Presents Preclinical Data for SENS-401 Demonstrating Protection against Cisplatin-Induced Hearing Loss in Animal Model

Read

Intensification of the Company’s international development with the appointment of a new CEO 

Read

Sensorion reports full year 2016 results in line with status of clinical development

Read

Next events